Leishmaniasis
Promising visceral leishmaniasis treatments must translate into actual therapy
Published in AIDS Weekly, March 21st, 2005
According to researchers in the United States, "In 2004, visceral leishmaniasis (kala-azar) maintains its status as a neglected, if not 'most neglected' disease.
"Lack of affordable new drugs, still a basic unsolved problem, has also been joined by additional therapeutic obstacles including large-scale resistance to pentavalent antimony (Sb) in India and coinfection with human immunodeficiency virus in all endemic regions."
"Nevertheless," said H.W. Murray and colleagues, "available treatment options have actually expanded because the energetic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-03-21)
More Articles from AIDS Weekly
- HIV/AIDS Pathogenesis
HIV-specific CTLs from long-term survivors select a unique T cell receptor - HIV/AIDS Prevention
High mobility among rural-urban migrants associated with increased sexual risk - HIV/AIDS Therapy
Protease inhibitors impair glucose-stimulated insulin secretion from beta cells - Reverse Transcriptase
AZT 5'-triphosphate mimics inhibit HIV reverse transcriptase - Aspergillosis
EIA/qPCR used to diagnose invasive aspergillosis in high-risk patients - Assisted Reproduction
IVF/ICSI safely avoids disease transmission in HIV-1 serodiscordant couples - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
